|
<Back
| Home | Basics |
Departments | Get
Involved | Site Map | What's
New

More Good News on Coconut Oil
by Mary G. Enig, PhD
One of the most serious and intractible medical problems facing doctors
today is that of antibiotic-resistant infectious microorganisms, the
so-called "superbugs." One example is MRSA (methicillin-resistant
Staphylococcus aureus), now a common source of blood poisoning
and infection in hospitals (see sidebar below). Other exampless of antibiotic-resistant
infectious agents include Bacillus anthracis Sterne, virulent
Escherichia coli, Klebsiela pneumoniae, Helicobacter
pylori, and Mycobacterium terrae, viruses with lipid membranes,
and a number of invasive fungi.
This problem has led to interest in researching the use of natural
products to enhance the treatment of infectious disease, such as coconut
oil and other oils rich in lauric acid as well as herbal remedies like
originum oil, substances traditionally recognized for decades for their
healing properties. While there have been many testimonies--so-called
"anecdotes"--about the effectiveness of such natural treatments,
until recently no published studies were available to doctors that would
allow them to justify their use of these protocols.
Fortunately coconut oil and other lauric oils, as well as oregano
oil, have recently been the object of study in the Georgetown University
laboratory of Dr. Harry Preuss in the United States and this research
has resulted in several published peer reviewed papers appearing in
toxicology journals in 2005.
The antimicrobial properties of both volatile aromatic oils such as
originum (oregano) oil and medium chain fatty acids such as lauric acid
and its derivative monolaurin from coconut oil have shown promise in
these studies. As noted by these researchers, origanum oil, used as
a food-flavoring agent, possesses a broad spectrum of antimicrobial
activity due, at least in part, to its high content of phenolic derivatives
such as carvacrol and thymol. Also, lauric acid, which is present in
heavy concentrations in coconut oil, forms monolaurin in the animal
body and this derivative of lauric acid can inhibit the growth of many
pathogenic microorganisms.
Part of the research focused on Staphylococcus aureus. In
vitro studies were performed on two strains of Staphylococcus aureus
and this was followed by in vivo studies in mice. The effects of monolaurin
and originum when used in combination were better than the most potent
antibiotic and this research showed that these safe antimicrobial agents
could be useful for prevention and therapy of Staphylococcus aureus
and numerous other infections.
It is now clear and scientifically validated that the inclusion of
coconut oil in the diet could and should be utilized for its preventive
and healing properties.
Resistant pathogens
Staphylococcus aureus (colloquially known as "Staph
aureus") is one of the major resistant pathogens. Found on
the mucous membranes and the skin of around a third of the population,
it is extremely adaptable to antibiotic pressure. It was the first
bacterium in which penicillin resistance was found--in 1947, just
four years after the drug started being mass-produced. Methicillin
was then the antibiotic of choice. MRSA (methicillin-resistant
Staphylococcus aureus) was first detected in Britain
in 1961 and is now "quite common" in hospitals. MRSA
was responsible for 37 percent of fatal cases of blood poisoning
in the UK in 1999, up from 4 percent in 1991. Half of all S.
aureus infections in the US are resistant to penicillin,
methicillin, tetracycline and erythromycin.
This left vancomycin as the only effective agent available at
the time. However, VRSA (Vancomycin-resistant Staphylococcus
aureus) was first identified in Japan in 1997, and has since
been found in hospitals in England, France and the US. VRSA is
also termed GISA (glycopeptide intermediate Staphylococcus
aureus) or VISA (vancomycin insensitive Staphylococcus
aureus), indicating resistance to all glycopeptide antibiotics.
A new class of antibiotics, oxazolidinones, became available
in the 1990s, and the first commercially available oxazolidinone,
linezolid, is comparable to vancomycin in effectiveness against
MRSA. Linezolid-resistance in Staphylococcus aureus was
reported in 2003.
Enterococcus faecium is another superbug found in hospitals.
Penicillin-Resistant Enterococcus was seen in 1983, Vancomycin-Resistant
Enterococcus (VRE) in 1987, and Linezolid-Resistant Enterococcus
(LRE) in the late 1990s.
Penicillin-resistant pneumonia (or pneumococcus, caused by Streptococcus
pneumoniae) was first detected in 1967, as was penicillin-resistant
gonorrhea. Resistance to penicillin substitutes is also known
beyond S. aureus. By 1993 Escherichia coli was
resistant to five fluoroquinolone variants. Mycobacterium
tuberculosis is commonly resistant to isoniazid and rifampin
and sometimes universally resistant to the common treatments.
Other pathogens showing some resistance include Salmonella,
Campylobacter, and Streptococci.
In November, 2004, the Centers for Disease Control and Prevention
(CDC) reported an increasing number of Acinetobacter baumannii
bloodstream infections in patients at military medical facilities
in which service members injured in the Iraq/Kuwait region during
military operations in Iraq and Afghanastan were treated. Most
of these showed multidrug resistance (MRAB), with a few isolates
resistant to all drugs tested (http://en.wikipedia.org/wiki/Antibiotic_resistance). |
REFERENCES
1. Preuss HG, Echard B, Enig M, Brook I, Elliott TB. Minimum inhibitory
concentrations of herbal essential oils and monolaurin for gram-positive
and gram-negative bacteria. Molecular Cell Biochemistry. 2005;272:29-34.
2. Preuss HG, Echard B, Dadgar A, Talpur N, Manohar V, Enig M, Bagchi
D, Ingram C. Effects of Essential Oils and Monolaurin on Staphylococcus
aureus: In Vitro and in Vivo Studies. Toxicology Mechanisms
and Methods 2005;15:279-285.
About the Author
Mary
G. Enig, PhD is an expert of international renown in the field of lipid
biochemistry. She has headed a number of studies on the content and effects of
trans fatty acids in America and Israel, and has successfully challenged
government assertions that dietary animal fat causes cancer and heart disease.
Recent scientific and media attention on the possible adverse health effects of
trans fatty acids has brought increased attention to her work. She is
a licensed nutritionist, certified by the Certification Board for Nutrition Specialists,
a qualified expert witness, nutrition consultant to individuals, industry and
state and federal governments, contributing editor to a number of scientific publications,
Fellow of the American College of Nutrition and President of the Maryland Nutritionists
Association. She is the author of over 60 technical papers and presentations,
as well as a popular lecturer. Dr. Enig is currently working on the exploratory
development of an adjunct therapy for AIDS using complete medium chain saturated
fatty acids from whole foods. She is Vice-President of the Weston A Price Foundation
and Scientific Editor of Wise Traditions as well as the author of Know
Your Fats: The Complete Primer for Understanding the Nutrition of Fats, Oils,
and Cholesterol, Bethesda Press, May 2000. She is the mother of three healthy
children brought up on whole foods including butter, cream, eggs and meat.
<Back
| Home | Tour
| Calendar | Contact
Us | Funding | Join
Now
|